O’Day Lays Out Plan For Gilead’s Continued HIV Dominance
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
You may also be interested in...
The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.
A first-in-class capsid inhibitor for HIV, lenacapavir has produced strong efficacy data for viral load reduction in treatment-experienced patients. The data measure up well against Viiv’s Rukobia, analyst says.
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.